Formerly dba Ave Maria Biotechnology (LLC)., AVM Biotechnology is structured around development of stem cell technologies designed to offer treatment in the form of regenerative medicine, immuno-oncology, and iPS cell fully human biologics. The company's G-CSF induced stem cell mobilization, GvHD, germinal centre lymphomas and iPS cell lines human biologics are enabling medical practitioners to have access to medicines with minimum side effects. The most recentnews about the firm is thatthey have received FDA IND approval to test their lead product AVM0703 for treatment of lymphoid malignancies. The mechanism of action that makes AVM0703 work against aggressive cancers may also prove effective against COVID-19. To further that research, AVM Biotechnology has filed with the FDA for approval to proceed with clinical trials against this virus as well as Influenza virus which also causes deadly ARDS.
